PLYX — what changed in the latest 10-Q
A section-by-section comparison of PLYX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +13 | −10 | ~30 | 37 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
Research and development expenses increased by $243 thousand to $719 thousand for the three months ended June 30, 2026, as compared to $476 thousand for the three months ended June 30, 2025. The increase in research and development expenses was primarily due to CRO expenses incurred for SOTERIA of $…
General and administrative expenses increased by $253 thousand to $661 thousand for the three months ended June 30, 2026, as compared to $408 thousand for the three months ended June 30, 2025, primarily due to increased public company related expenses incurred in connection with the direct listing i…
The following table summarizes our statements of operations for the periods presented.
Research and development expenses decreased by $3.8 million to $1.4 million for the six months ended June 30, 2026, as compared to $5.2 million for the six months ended June 30, 2025. The reduction in research and development expenses was primarily due to stock-based compensation of approximately $4…
General and administrative expenses increased by $1.2 million to $1.9 million for the six months ended June 30, 2026, as compared to $744 thousand for the six months ended June 30, 2025, primarily due to increased public company related expenses incurred in connection with the direct listing in Janu…
Text removed vs the prior filing · source: 10-Q · 2026-05-15
Comparison of the Three Months Ended March 31, 2026 and 2025
Research and development expenses decreased by $4.0 million to $679 thousand for the three months ended March 31, 2026, as compared to $4.7 million for the three months ended March 31, 2025. The reduction in research and development expenses was primarily due to stock-based compensation of approxima…
General and administrative expenses increased by $943 thousand to $1,279 thousand for the three months ended March 31, 2026, as compared to $336 thousand for the three months ended March 31, 2025, primarily due to increased public company related expenses incurred in connection with the direct listi…
Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our programs. From our inception through the filing date of this Quarterly Report, we have funded our …
The following table presents the Company’s cash and cash equivalents as of March 31, 2026 and December 31, 2025:
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice